Different Immunosuppressive Treatment in iMN
ConditionIdiopathic Membranous Nephropathy
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorPeking Union Medical College Hospital
About this trial
The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)
Eligibility criteria
Qualifiers
idiopathic membranous nephropathy
Female, must be post-menopausal, sterile or have effective contraception
must be off steroid or mycophenolate mofetil for >1 month and alkylating agents for or RTX> 6 months
Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for ≥ 3 months with controlled blood pressure prior to beginning of immunosuppressive therapy or if patients are intolerant to ACEI/ARB.
Disqualifiers
presence of active infection or a secondary cause of membranous nephropathy
proteinuria associated with diabetic nephropathy
pregnancy or breast feeding
history of resistance to rituximab or alkylating agents or corticosteroid
Trial design
Treatments tested in this trial
- Prednisone
- Cyclophosphamide
- Rituximab
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov